Dirithromycin: Difference between revisions
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
Gerald Chi (talk | contribs) m (Changed protection level for "Dirithromycin" ([Edit=Allow only autoconfirmed users] (expires 19:46, 22 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 19:46, 22 January 2014 (UTC)))) |
(No difference)
|
Revision as of 19:46, 8 January 2014
File:Dirithromycin.svg | |
Clinical data | |
---|---|
[[Regulation of therapeutic goods |Template:Engvar data]] |
|
Pregnancy category |
|
ATC code | |
Pharmacokinetic data | |
Bioavailability | 10% |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C42H78N2O14 |
Molar mass | 835.074 g/mol |
WikiDoc Resources for Dirithromycin |
Articles |
---|
Most recent articles on Dirithromycin Most cited articles on Dirithromycin |
Media |
Powerpoint slides on Dirithromycin |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Dirithromycin at Clinical Trials.gov Trial results on Dirithromycin Clinical Trials on Dirithromycin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Dirithromycin NICE Guidance on Dirithromycin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Dirithromycin Discussion groups on Dirithromycin Patient Handouts on Dirithromycin Directions to Hospitals Treating Dirithromycin Risk calculators and risk factors for Dirithromycin
|
Healthcare Provider Resources |
Causes & Risk Factors for Dirithromycin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Dirithromycin is a macrolide glycopeptide antibiotic.
Dirithromycin (Dynabac) is a more lipid-soluble prodrug derivative of 9S-erythromycyclamine prepared by condensation of the latter with 2-(2-methoxyethoxy)acetaldehyde. The 9N, 11O-oxazine ring thus formed is a hemi-aminal that is unstable under both acidic and alkaline aqueous conditions and undergoes spontaneous hydrolysis to form erythromycyclamine. Erythromycyclamine is a semisynthetic derivative of erythromycin in which the 9-ketogroup of the erythronolide ring has been converted to an amino group. Erythromycyclamine retains the antibacterial properties of erythromycin oral administration. The prodrug, dirithromycin, is provided as enteric coated tablets to protect it from acid catalyzed hydrolysis in the stomach. Orally administered dirithromycin is absorbed rapidly into the plasma, largely from the small intestine. Spontaneous hydrolysis to erythromycyclamine occurs in the plasma. Oral bioavailability is estimated to be about 10%, but food does not affect absorption of the prodrug.
Discontinuation
Dirithromycin is no longer available in the United States.[1] The U.S. National Institutes of Health recommend that people taking dirithromycin consult their physicians to discuss switching to another treatment.[2]
References
- ↑ "Dynabac Drug Details". U.S. Food and Drug Administration. Retrieved 2007-05-25.
- ↑ "Dirithromycin". MedlinePlus. U.S. National Library of Medicine. January 1 2006. Retrieved 2007-05-25. Check date values in:
|date=
(help)
- Pages with script errors
- CS1 errors: dates
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Macrolide antibiotics
- Prodrugs